Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696789 | 0.85 | TSHR (0.39) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL8051642 | 0.76 | MAPT (0.45) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL3704781 | 0.72 | ALDH1A1 (0.38) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL3701490 | 0.69 | BAZ1A (0.31) | NPC1RAB9AMEN1KMT2ABAZ1A | |
| SCHEMBL9668300 | 0.68 | DPP4 (0.44) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL8057091 | 0.67 | BAZ1A (0.41) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL6247069 | 0.66 | MAPK1 (0.46) | POLBTDP1MEN1KMT2AMAPT | |
| SCHEMBL13589128 | 0.66 | POLB (0.42) | NPC1RAB9APOLBTDP1MEN1 | |
| SCHEMBL9668093 | 0.66 | BAZ1A (0.40) | NPC1RAB9APOLBMEN1KMT2A | |
| Potassium Ion SCHEMBL3711222 | 0.66 | RAD51 (0.33) | KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9079830-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | NPC1 1442/4885RAB9A 856/4885POLB 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.